Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus

Author(s): Fahmida Alam, Mohammad A. Kamal, Md. Asiful Islam, Shaheena Banu.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 19 , Issue 6 , 2019

Become EABM
Become Reviewer

[1]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[2]
Hwang, J.Y.; Lee, H.J.; Go, M.J.; Jang, H.B.; Choi, N.H.; Bae, J.B.; Castillo-Fernandez, J.E.; Bell, J.T.; Spector, T.D.; Lee, H.J.; Kim, B.J. Genome-wide methylation analysis identifies ELOVL5 as an epigenetic biomarker for the risk of type 2 diabetes mellitus. Sci. Rep., 2018, 8(1), 14862.
[http://dx.doi.org/10.1038/s41598-018-33238-9] [PMID: 30291282]
[3]
Cirillo, E.; Kutmon, M.; Gonzalez Hernandez, M.; Hooimeijer, T.; Adriaens, M.E.; Eijssen, L.M.T.; Parnell, L.D.; Coort, S.L.; Evelo, C.T. From SNPs to pathways: Biological interpretation of type 2 diabetes (T2DM) genome wide association study (GWAS) results. PLoS One, 2018, 13(4)e0193515
[http://dx.doi.org/10.1371/journal.pone.0193515] [PMID: 29617380]
[4]
Liu, Y.; Zhao, J.; Jiang, T.; Yu, M.; Jiang, G.; Hu, Y. A pathway analysis of genome-wide association study highlights novel type 2 diabetes risk pathways. Sci. Rep., 2017, 7(1), 12546.
[http://dx.doi.org/10.1038/s41598-017-12873-8] [PMID: 28970525]
[5]
Barseem, N.F.; El Ella, S.S.A.; Tawfik, M.A.; El-Nehrawy, R.R. The Potential implication of FTO rs17817449 gene polymorphism on bmi mediated risk for type2 diabetes among obese Egyptian children and adolescents. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(5), 697-704.
[http://dx.doi.org/10.2174/1871530319666190101124751] [PMID: 30621571]
[6]
Rabiee, M.; Marjani, A.; Khajeniazi, S.; Mojerloo, M. Genetic polymorphisms of cytochrome p450 (2c9) enzyme in patients with type 2 diabetes mellitus in Turkmen and fars ethnic groups. Endocr. Metab. Immune Disord. Drug Targets, 2018, 18(6), 653-661.
[http://dx.doi.org/10.2174/1871530318666180821122853] [PMID: 30129421]
[7]
Stols-Gonçalves, D.; Tristão, L.S.; Henneman, P.; Nieuwdorp, M. Epigenetic markers and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease. Curr. Diab. Rep., 2019, 19(6), 31.
[http://dx.doi.org/10.1007/s11892-019-1151-4] [PMID: 31044315]
[8]
Sommese, L.; Benincasa, G.; Lanza, M.; Sorriento, A.; Schiano, C.; Lucchese, R.; Alfano, R.; Nicoletti, G.F.; Napoli, C. Novel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes. J. Diabetes Complications, 2018, 32(11), 1076-1084.
[http://dx.doi.org/10.1016/j.jdiacomp.2018.08.012] [PMID: 30190170]
[9]
Ahmed, S.M.; Johar, D.; Ali, M.M.; El-Badri, N. Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 742-750.
[http://dx.doi.org/10.2174/1871530319666190305131813] [PMID: 30834843]
[10]
Johar, D.; Ahmed, S.M.; El Hayek, S.; Al-Dewik, N.; Bahbah, E.I.; Omar, N.H.; Mustafa, M.; Salman, D.O.; Fahmey, A.; Mottawea, M.; Azouz, R.A.M.; Bernstein, L. Diabetes-Induced Proteome Changes Throughout Development. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 730-741.
[PMID: 31038056]
[11]
Tiwari, P.; Katyal, A.; Khan, M.F.; Ashraf, G.M.; Ahmad, K. Lead Optimization Resources in Drug Discovery for Diabetes. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 751-770.
[http://dx.doi.org/10.2174/1871530319666190304121826] [PMID: 30834844]
[12]
Hossan, T.; Kundu, S.; Alam, S.S.; Nagarajan, S. Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 771-781.
[http://dx.doi.org/10.2174/1871530319666190301145545] [PMID: 30827271]
[13]
Khatami, F.; Mohajeri-Tehrani, M.R.; Tavangar, S.M. The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 719-729.
[http://dx.doi.org/10.2174/1871530319666190228102212] [PMID: 31122183]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 6
Year: 2019
Page: [717 - 718]
Pages: 2
DOI: 10.2174/187153031906190724104004

Article Metrics

PDF: 21
HTML: 5
EPUB: 1
PRC: 1